Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 16/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.34 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200622 | 0.92 | TYRO3 (0.34) | KCNH2TYRO3MERTKCDK9 | |
| SCHEMBL2196440 | 0.91 | NTRK1 (0.35) | TYRO3MERTK | |
| SCHEMBL2198979 | 0.90 | IGF1R (0.38) | CDK2JUNMAPK8MAPK9IGF1R | |
| SCHEMBL2200780 | 0.89 | PLK1 (0.36) | CDK2IGF1RKCNH2TYRO3MERTK | |
| SCHEMBL2195962 | 0.86 | FLT3 (0.44) | CDK2JUNMAPK8MAPK9 | |
| SCHEMBL2198230 | 0.83 | ADRB2 (0.35) | IGF1R | |
| SCHEMBL2195698 | 0.83 | IGF1R (0.36) | CDK2IGF1RKCNH2 | |
| SCHEMBL2198357 | 0.81 | IGF1R (0.35) | CDK2IGF1RCDK1 | |
| SCHEMBL2197154 | 0.81 | IGF1R (0.35) | CDK2IGF1RCDK1 | |
| SCHEMBL4258682 | 0.81 | IGF1R (0.35) | CDK2IGF1RCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | CDK2 23/4885JUN 3772/4885MAPK8 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.